Condition
Obesity
Locations
Belgium, France, Greece, Poland, United States
Start date
17/09/2024
Identifiers
Trial ID
NN9536-7752,
NCT number NCT06571383,
Eudract number Not Available
NCT number NCT06571383,
Eudract number Not Available
Summary
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Trial Overview:
Treatment
DRUG: Semaglutide
Study type
INTERVENTIONAL
Trial duration
Sep 17 2024 - Nov 15 2031
Participants
500
Phase
IIII
Are you eligible?
Gender
Male and female
Age
12 to 15 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.